Serum and Urinary Biomarkers of Acute Kidney Injury
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Acute kidney injury (AKI) is a frequent clinical problem in critically ill patients and the associated mortality is high. Standard serum and urine biomarkers are insensitive and nonspecific for the detection of kidney injury in its early stages which limits the therapeutic options and may compromise the outcome. The study presents new candidates for biochemical markers of AKI, with potentially high sensitivity and specificity, causally related to its pathogenesis and development. Some of these biomarkers measured in serum or urine are well known in laboratory practice but have been used in other tests, while some novel biomarkers have been proposed as a result of experimental and clinical studies. In current clinical practice, identification and classification of AKI is based on elevations in serial serum creatinine concentrations, which are delayed and therefore unreliable in the acute setting. The most promising of the new serum AKI markers are cystatin C, neutrophil gelatinase-associated lipocalin and uric acid. Urinary AKI markers may be classified as enzymes released from damaged tubular cells (alkaline phosphatase, γ-glutamyl transpeptidase, alanine aminopeptidase, isoenzymes of glutathione transferase, N-acetyl-β-D-glucosaminidase), low-molecular-weight proteins (α 1-microglobulin, β 2-microglobulin, retinol-binding protein, cystatin C) and proteins specifically produced in the kidney and associated with the development of AKI [cysteine-rich protein 61, neutrophil gelatinase-associated lipocalin, kidney injury molecule 1, cytokines and chemokines (Gro-α, IL-18), and structural and functional proteins of renal tubules (F-actin, Na+/H+ exchange isoform 3)]. Based on the different expression of these markers, using a panel of serum and urine markers may potentially help to distinguish between various types of insults, establish the duration and severity of injury, predict the clinical outcome and help to monitor response to treatment in AKI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mishra, J., Ma, Q., Prada, A., Mitsnefes, M., Zahedi, K., Yang, J., Barasch, J., & Devarajan, P. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000088027.54400.c6 · Cited by 1,749 · cited 1×
“Recently, many authors have proposed serum uric acid measurements for early detection and assessment of AKI development. Much is known about the association between hyperuricemia and acute urate nephropathy, but increased serum concentrations of uric acid have also been demonstrated in many other types of AKI. Since e…”
BackgroundDent, C. L., Ma, Q., Dastrala, S., Bennett, M., Mitsnefes, M. M., Barasch, J., & Devarajan, P. (2007) · Critical Care · doi:10.1186/cc6192 · Cited by 483 · cited 1×
“The devastating course of AKI explains the growing interest of clinicians in effective protection against the consequences of the disease, based upon its early detection and assessment of the clinical course and prognosis, allowing institution of effective treatment [ , , , , , ,”
Background
Cited by
Boron Containing Compounds as Protease Inhibitors
Smoum, R., Rubinstein, A., Dembitsky, V. M., & Srebnik, M. (2012) · Chemical Reviews · doi:10.1021/cr608202m · Cited by 450
Metadata
- Authors
- Lisowska-Myjak, B.
- Venue
- Blood Purification
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 29
- Issue
- 4
- Pages
- 357-365
- ISSN
- 0253-5068 (ISSN-L)
- 1421-9735
- OpenAlex
- W2020017742
- Cited by
- 200
- References
- 2
- FWCI
- 13.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum and Urinary Biomarkers of Acute Kidney Injury. https://app.cochat.ai/papers/10.1159/000309421
- The paper
- Lisowska-Myjak, B. (2010). Serum and Urinary Biomarkers of Acute Kidney Injury. Blood Purification. https://doi.org/10.1159/000309421
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.